πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 39 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12364680

Compounds for treating ophthalmic diseases and disorders

KIORA PHARMACEUTICALS GmbH Β· Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12128036

Compositions and methods for storage stable ophthalmic drugs

LENZ THERAPEUTICS OPERATIONS, INC. Β· Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12005139

Ophthalmic formulations and related methods

ETERNATEAR, INC. Β· Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12005060

Ophthalmic formulations of methotrexate

Aldeyra Therapeutics, Inc. Β· Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12005061

Ophthalmic formulations of methotrexate

Aldeyra Therapeutics, Inc. Β· Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11964047

Ophthalmic formulations and related methods

ETERNATEAR, INC. Β· Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11925686

Materials for phototherapies of ophthalmic diseases

EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD. Β· Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11845989

Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11820982

Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitors

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11786518

Ophthalmic formulations and uses thereof

Aldeyra Therapeutics, Inc. Β· Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11767526

Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11752137

Ophthalmic compositions for treating ocular Demodex using lotilaner formulations

Tarsus Pharmaceuticals, Inc. Β· Granted Tue Sep 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11730716

Compounds for treating ophthalmic diseases and disorders

KIORA PHARMACEUTICALS GmbH Β· Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11684570

Pharmaceutical ophthalmic compositions

EYE CARE NORTHWEST, PA Β· Granted Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11679079

Ophthalmic formulations and related methods

ETERNATEAR, INC. Β· Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11679078

Ophthalmic formulations and related methods

ETERNATEAR, INC. Β· Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11512309

Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11439590

Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabr

PYP CAR NORTHWEST, PA Β· Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11285163

Ophthalmic solution

SENTISS PHARMA PRIVATE LIMITED Β· Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11278493

Ophthalmic formulations providing durable ocular lubrication

ETERNATEAR, INC. Β· Granted Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10973871

Ophthalmic compositions

AURINIA PHARMACEUTICALS INC. Β· Granted Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10517869

Topical brimonidine tartrate ophthalmic solution

SENTISS PHARMA PRIVATE LIMITED Β· Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10463674

Process for manufacturing sterile ophthalmic pharmaceutical suspensions

SENTISS PHARMA PRIVATE LIMITED Β· Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10265375

Ophthalmic compositions

AURINIA PHARMACEUTICALS INC. Β· Granted Tue Apr 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted